Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation

Musa Khaitov1, Alexandra Nikonova1, Ilya Kofjadi1, Igor Shilovskiy1, Valeriy Smirnov1, Olga G. Elisyutina1, Artem Maerle1, Artem Shatilov1, Anastasia Timofeeva1, Sergey Andreev1, Ilya Sergeev1, Tatyana Latysheva1, Nataliya Ilina1, Alexander Martynov1, Sevastyan Rabdano2, Ellina Ruzanova2, Nikita Savelev2, Iuliia Pletiukhina2, Ariana Safi2, Vyacheslav Ratnikov3, Viktor Gorelov3, Viktor Kaschenko3, Natalya Kucherenko3, Irina Umarova3, Svetlana Moskaleva3, Sergei Fabrichnikov3, Oleg Zuev4, Nikolai Pavlov4, Daria Kruchko5, Igor Berzin5, Dmitriy Goryachev6, Vadim Merkulov7, Victor Trukhin2, Rudolf Valenta1, and Veronica Skvortsova5

1FGBU Gosudarstvennyj naucnyj centr Institut immunologii Federal’nogo mediko-biologiceskogo agentstva Rossi
2FGUP Sankt-Peterburgskij naucono-issledovatel’skij institut vakcin i syvorotok i predpriatie po proizvodstvu bakterijnyh preparatov FMBA Rossi
3FGBUZ Kliniceskaa bol’nica No 122 imeni L G Sokolova Federal’nogo mediko-biologiceskogo agentstva Rossi
4Federal Clinical Center of High Medical Technologies of the Federal Medical and Biological Agency of Russia
5Federal’noe mediko-biologiceskoe agentstvo Rossi
6Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation
7Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Secenova

October 30, 2022

Abstract

BACKGROUND Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation (MIR 19®) targeting a conserved sequence in known SARS-CoV-2 variants for treatment of COVID-19. METHODS We conducted an open-label, randomized controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled MIR 19® (3.7mg and 11.1 mg/day: groups 1 and 2, respectively) in comparison with standard etiotropic drug treatment (group 3) in patients hospitalized with moderate COVID-19. The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization. RESULTS Patients from group 1 had a significantly reduced (median 6 days (95% confidence interval [CI]: 5-7, HR 1.75, P=0.0005) time to clinical improvement compared to patients from group 3 (8 days (95% CI: 7-10). Normalized oxygen saturation (SpO2 >94%) occurred quicker in the group 1 (median 5 days (95% CI: 4-5, HR 1.59, P=0.0033) than in the group 3 (6 days, 95% CI: 5-8). Treatment with MIR 19® was well tolerated and safe. CONCLUSIONS MIR 19®, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe and significantly reduces time to clinical improvement in hospitalized moderate COVID-19 patients compared to standard therapy in a randomized controlled trial. MIR 19® treatment targets a sequence which is identical in all SARS-CoV-2 variants known so far and hence should be applicable for all of them.
Hosted file


Hosted file